Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

St. Jude Children's Research Hospital scientists identified a promising combination approach to treat a rare, but ...

A new international study has delivered a rare dose of good news in the fight against aggressive brain tumors. Researchers ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

By improving BP control and treatment adherence, use of fixed-dose combination therapies is expected to drive down CV events ...

Sustained long-term safety data for tildrakizumab strengthens the positioning of IL-23 inhibitors as a preferred choice, ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive ...

Please provide your email address to receive an email when new articles are posted on . In patients with pulmonary arterial hypertension, many initially receive just one drug of the combination ...

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with reassurance, ...